NewsFeeder
Headline News
Gilead signs on for another oncology deal, this time with Jounce Therapeutics
Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.'s tumor-infiltrating T regulatory cells program. Jounce, which said it plans to submit the antibody treatment to the Food and Drug Administration in the first half of next year, saw shares soar 91.7% in premarket trading on Tuesday. Gilead is paying $85 million upfront, making a $35 million investment if the deal closes, and allowing for up to $685 million in milestone payments. This is the latest in a handful of oncology deals that Gilead has engaged in 2020, including a $4.7 billion acquisition of Forty Seven Inc. and a $275 million stake in Pionyr Immunotherapeutics Inc. However, Gilead's stock has struggled to regain momentum from its year-to-date high in April, when it reported the first batch of clinical data for its experimental COVID-19 drug remdesivir. Gilead's stock is up 2.7% for the year, while the S&P 500 has gained 8.3% since the start of the year.
https://finance.yahoo.com/m/44b36e1...d3/gilead-signs-on-for-another.html?.tsrc=rss
Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.'s tumor-infiltrating T regulatory cells program. Jounce, which said it plans to submit the antibody treatment to the Food and Drug Administration in the first half of next year, saw shares soar 91.7% in premarket trading on Tuesday. Gilead is paying $85 million upfront, making a $35 million investment if the deal closes, and allowing for up to $685 million in milestone payments. This is the latest in a handful of oncology deals that Gilead has engaged in 2020, including a $4.7 billion acquisition of Forty Seven Inc. and a $275 million stake in Pionyr Immunotherapeutics Inc. However, Gilead's stock has struggled to regain momentum from its year-to-date high in April, when it reported the first batch of clinical data for its experimental COVID-19 drug remdesivir. Gilead's stock is up 2.7% for the year, while the S&P 500 has gained 8.3% since the start of the year.
https://finance.yahoo.com/m/44b36e1...d3/gilead-signs-on-for-another.html?.tsrc=rss
